(Q38901610)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Judith Bovée

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Pancras C.W. Hogendoorn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Erik Danen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Zuzanna Baranski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Anne-Marie Cleton-Jansen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Leo S Price

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Bob van de Water

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

30 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

348-359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25757065%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?

2 March 2020

cites work

1 reference

Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1

21 January 2018

1 reference

Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL.

21 January 2018

1 reference

An Integrated Bioinformatics and Computational Biology Approach Identifies New BH3-Only Protein Candidates

21 January 2018

1 reference

Aven-dependent activation of ATM following DNA damage

21 January 2018

1 reference

Activation of ATR and related PIKKs

21 January 2018

1 reference

DNA damage-induced activation of ATM and ATM-dependent signaling pathways

21 January 2018

1 reference

Chk1 and Chk2 kinases in checkpoint control and cancer

21 January 2018

1 reference

Anticancer therapy with checkpoint inhibitors: what, where and when?

21 January 2018

1 reference

Survivin and aven: two distinct antiapoptotic signals in acute leukemias

21 January 2018

1 reference

Aven overexpression: association with poor prognosis in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms

21 January 2018

1 reference

Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data.

21 January 2018

1 reference

Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

21 January 2018

1 reference

Functional characterization of osteosarcoma cell lines provides representative models to study the human disease

21 January 2018

1 reference

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort

21 January 2018

1 reference

Systematic discovery of multicomponent therapeutics

21 January 2018

1 reference

Aven and Bcl-xL enhance protection against apoptosis for mammalian cells exposed to various culture conditions

21 January 2018

1 reference

Cell-cycle checkpoints and cancer

21 January 2018

1 reference

Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control

21 January 2018

1 reference

CHK2 kinase--a busy messenger.

21 January 2018

1 reference

ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks

21 January 2018

1 reference

ATM regulates ATR chromatin loading in response to DNA double-strand breaks

21 January 2018

1 reference

The DNA damage response: ten years after

21 January 2018

1 reference

CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy

21 January 2018

1 reference

Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary

21 January 2018

1 reference

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells

21 January 2018

1 reference

Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

21 January 2018

1 reference

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

21 January 2018

1 reference

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

21 January 2018

1 reference

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer

21 January 2018

1 reference

Osteosarcoma treatment - where do we stand? A state of the art review.

21 January 2018

1 reference